Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Sickle Cell Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Sickle Cell DiseasePipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Sickle Cell DiseasePipeline Drugs Assessment

 

Overview:

Sickle-cell diseases (SCD) are types of blood disorders which are usually inherited genetically. One of the common types of SCDs is the sickle-cell anemia or SCA. It essentially gives rise to an irregularity in hemoglobin, the protein that carries oxygen in the blood. Hemoglobin is found typically in the red blood cells of the body. As a result, a sickle-like shaped cell is formed under certain conditions. Tribulations in sickle cell disease usually start to take shape at a very early age (within the first year of birth). This might lead to various health problems including pain attacks also known as the sickle-cell crisis, swelling in the limbs, microbial infections, and in certain cases, stroke. SCD is diagnosed by blood tests and Hb electrophoresis. Hydroxyurea is the only FDA approved drug for treatment of Sickle-cell diseases.

 

Segmentation:

By Trial Phase, Sickle Cell Diseasepipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Sickle Cell Diseasepipeline drugs are segmented as:

  • Eli Lilly and Company
  • NKT Therapeutics
  • AstraZeneca
  • Novartis
  • bluebird bio
  • BioMarin Pharmaceutical
  • Imara, Inc.
  • Mast Therapeutics, Inc.
  • Pfizer
  • Sanofi
  • Endo Pharmaceuticals
  • Others

By Drugs, Sickle Cell Disease pipeline drugs are segmented as:

  • Prasugrel
  • Sevuparin
  • L-Citruline
  • Ticagrelor
  • Docosahexaenoic Acid
  • sapropterindihydrochloride
  • Treprostinil
  • Deferiprone
  • Others

By Type of Disease, Sickle Cell Disease pipeline drugs are segmented as:

  • Sickle cell anemia
  • Sickle cell hemoglobin C disease
  • Sickle cell thalassemia disease

By Route of Administration, Sickle Cell Diseasepipeline drugs are segmented as:

  • Oral
  • Parenteral

 

Space Analysis:

  • In December 2017, Novartis Pharmaceuticals released results of post hoc subgroup analysis of the Phase II SUSTAIN study of crizanlizumaban investigational humanized anti-P-selectin monoclonal antibody determined that crizanlizumab delayed the time to first sickle cell pain crisis in patients vs. placebo in key subgroups of adult patients with sickle cell disease
  • In February 2017, bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease.

 

Report Description:

Sickle Cell DiseaseDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Sickle Cell Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Sickle Cell Diseasedisease pipeline drugs development. This report studies the dynamics of the Sickle Cell DiseaseDisease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Sickle Cell Diseasedisease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

 

  • Eli Lilly and Company
  • NKT Therapeutics
  • AstraZeneca
  • Novartis
  • bluebird bio
  • BioMarin Pharmaceutical
  • Imara, Inc.
  • Mast Therapeutics, Inc.
  • Pfizer
  • Sanofi
  • Endo Pharmaceuticals

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553